Immune inhibitory effects of renal cell carcinoma extract on lectin and alloantigen-induced peripheral blood and tumor infiltrating lymphocyte blastogenesis

Urologic Oncology: Seminars and Original Investigations

Volumn 21, Issue 1, 2003, Pages 27-32

  Shabtai, M ^a,b   Ye, H ^a   Kono, K ^a   Takayam, T ^a   Terashima, K ^a   Tsukuda, K ^a   Frischer, Z ^a   Waltzer, W C ^a   Malinowski, K ^a  

^a STONY BROOK UNIVERSITY   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Peripheral blood lymphocytes; Renal cell carcinoma; Tumor infiltrating lymphocytes

Indexed keywords

ALLOANTIGEN; CONCANAVALIN A; LECTIN; PHYTOHEMAGGLUTININ; POKEWEED MITOGEN; TUMOR EXTRACT; BIOLOGICAL FACTOR; TISSUE EXTRACT;

ADULT; AGED; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNE DEFICIENCY; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFORMATION; MALE; NEPHRECTOMY; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE; ADENOCARCINOMA; ANTIBODY SPECIFICITY; BLOOD CELL; CELL CULTURE; CHEMISTRY; COMPARATIVE STUDY; DRUG EFFECT; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; ISOLATION AND PURIFICATION; KIDNEY; KIDNEY TUMOR; LYMPHOCYTE ACTIVATION; MIDDLE AGED; TRANSITIONAL CELL CARCINOMA;

ADENOCARCINOMA, CLEAR CELL; AGED; BIOLOGICAL FACTORS; BLOOD CELLS; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; CELLS, CULTURED; CONCANAVALIN A; FEMALE; HUMANS; IMMUNE TOLERANCE; ISOANTIGENS; KIDNEY; KIDNEY NEOPLASMS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; ORGAN SPECIFICITY; PHYTOHEMAGGLUTININS; POKEWEED MITOGENS; TISSUE EXTRACTS;

EID: 0141957152     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-1439(02)00199-0     Document Type: Article

References (23)

1. Bouet-Toussaint F, Genetel N, Rioux-Leclercq N, et al. Interleukin-2 expanded lymphocytes from lymph nodes and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer. Eur Cytok Ntwrk 2000;11:217-24.
2. Elssaser-Beile U, Rindsfuser M, Grussenmeyer T, Schiltze-Seeman W, Wetterrauer U. Enhanced expression of INF-gamma mRNA in CD4(+) or CD8(+) tumor-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer. Br J Cancer 2000;83:637-41.
3. Worford LJ, Burowski R, Tubbs R, et al. Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clin Cancer Res 1999;5:1219-29.
4. Border S, Waldmann TA. The suppressor cell network (part one). A review. N Engl J Med 1978;299:1281-4.
5. Hersh EM, Oppenheim JJ. Impaired in vitro lymphocyte transformation in Hodgkin s disease. N Engl J Med 1965;273:1006-12.
6. Brasanac D, Muller CA, Muller GA, Hadzi-Dzokic J, Markovic-Lipovski J. HLA class I antigens expression in renal cell carcinoma: histopathological and clinical correlation. J Exp Clin Cancer Res 1999;18:505-10.
7. Brasanac D, Markovic-Lipovski, Hadzi-Dzokic J, Muller GA, J Muller CA. Immunohistochemical analysis of HLA class II antigens and tumor infiltrating mononuclear cells in renal cell carcinoma: correlation with clinical and histopathological data. Neoplasma 1999;46: 173-8.
8. Steiner T, Junker U, Wunderlich H, Schubert J. Are renal cell carcinoma cells able to modulate the cytotoxic effect of tumor infiltrating lymphocytes by secretion of interleukin-6? Anticancer Res 1999;19: 1533-6.
9. Kobayashi H, Tanaka Y, Taji J, Toma H, Uchiyama T. Gamma/delta T cells provide innate immunity against renal cell carcinoma. Cancer Immunol Immunother 2001;50:115-24.
10. Elsasser-Beile U, Grussenmeyer T, Giercshner D, et al. Semi-quantitative analysis of Th1 and Th2 cytokine expression in CD3+, CD4+ and CD8+ renal cell carcinoma infiltrating lymphocytes. Cancer Immunol Immunother 1999;48:204-8.
11. Ulchaker J, Panuto J, Rayman P, et al. Interferron-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12. J Immunother 1999; 22:71-9.
12. Troy AJ, Summers KL, Daidson PJ, Atkinson CH, Hart DN. Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin Cancer Res 1998;4:585-93.
13. Lee KH, Panelli MC, Kim CJ, et al. Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 1998;161:4183-94.
14. Nabel GJ, Gordon D, Bishop DK, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA 1996;93:15388-93.
15. Malinowski K, Kono K, Takayama T, et al. Inhibition of lymphocyte proliferative response by renal cell carcinoma extract. Transpl Proc 1997;29:839-41.
16. Sela BA, Llipoulus D, Guerry D, et al. Levels of disialogangliosides in sera of melanoma patients monitored by sensitive thin-layered chromatography and immunostaining. J Natl Cancer Inst 1989;81: 1489-92.
17. Ladisch S, Wu ZL. Detection of tumor associated gangliosides in plasma of patients with neuroblastoma. Lancet 1 1985;1(8421):136-8.
18. Bergelsom LD. Serum gangliosides as endogenous immunomodulators. Immunol Today 1995;16:483-6.
19. Schendel BJ, Gansbacher B, Oberneder R, et al. Tumor-specific lysis of human renal cell carcinomas by tumor infiltrating lymphocytes. I. HLA-A2-restricted recognition of autologous and allogeneic tumor lines. J Immunol 1993;151:4209-20.
20. Irani DN, Lin KI, Griffin DE. Brain-derived gangliosides regulate the cytokine production and proliferation of activated T cells. J Immunol 1996;157:4333-40.
21. Lu P, Sharom FJ. Immunosuppression by YAC-I lymphoma: role of shed gangliosodes. Cell Immunol 1996;173:22-32.
22. Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immune suppression. Immunology 2001;103:131-6.
23. Kanda M. Gangliosides GD1a and GM3 induce interleukin-10 production by human T cells. Biochem Biophys Res Commun 1999;256: 41-4.